Any website or individual claiming to supply CagriSema or cagrilintide outside of a clinical trial is operating unlawfully and posing a serious risk to patient safety
Kuo B, Scimia C, Dukes G et al (2021) Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis
The GLP-1 revolution, which started with relatively modest single-agonist drugs, has progressed to dual-agonists, then triple-agonists, and the pipeline continues to expand
p = 0.07), indicating a large level of disparity between the two treatments (Figure 3)
Complete dosing chart at 10mg/ml (1ml of bacteriostatic water) Notice the problem at the 1.25mg microdose level
PMID 17077356